BIOGEN INC. (BIIB) Financial Ratio Screen
Track BIIB screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
BIIB financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Drug Manufacturers - General) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: SEC filing extraction found 30 dimensioned facts; 0 have passed extraction review. No activity conclusion is made. Open the SEC annual filing.
View SEC-extracted business segments
- Reportable Segment — 100.0% of filing total · extraction pending
- Product — 72.0% of filing total · extraction pending
- MSProduct Revenues — 40.8% of filing total · extraction pending
- Rare Disease Product Revenue — 21.8% of filing total · extraction pending
- Revenues From Anti CD20Therapeutic Programs — 18.8% of filing total · extraction pending
- Tysabri Product — 16.8% of filing total · extraction pending
- SPINRAZA — 15.6% of filing total · extraction pending
- Fumarate — 14.4% of filing total · extraction pending
- Royalty Attributed To OCREVUS — 14.3% of filing total · extraction pending
- Interferon — 9.6% of filing total · extraction pending
- VUMERITY — 7.6% of filing total · extraction pending
- Contract Manufacturing Royalty And Other Revenue — 7.4% of filing total · extraction pending
Profile description reviewed: Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 22.3% / 30% | 13.0% / 30% | 19.3% / 30% | 1.26% / 5% | FINANCIAL SCREEN PASSED* |
| S&P-style (provisional) | 23.9% / 33% | N/A | N/A | 1.26% / 5% | FINANCIAL SCREEN PASSED* |
| FTSE | 22.3% / 33% | 13.0% / 33% | 19.3% / 50% | 1.26% / 5% | FINANCIAL SCREEN PASSED* |
Financial Highlights
Profitability
| Gross Margin | 78.3% | |
| Operating Margin | 25.1% | |
| Net Margin | 8.3% | |
| Return on Equity (ROE) | 4.6% | |
| Return on Assets (ROA) | 5.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $2.2B |
| Free Cash Flow | $2.0B |
| Total Debt | $6.6B |
| Debt-to-Equity | 44.3 |
| Current Ratio | 1.9 |
| Total Assets | $29.4B |
Price & Trading
| Last Close | $214.35 |
| 50-Day MA | $205.27 |
| 200-Day MA | $187.99 |
| Avg Volume | 1.2M |
| Beta | 0.2 |
|
52-Week Range
$131.52
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-08-24 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Historical market-cap evidence
37 monthly estimates are retained from
2023-07-31 to
2026-07-31. Each point combines a
month-end close from
Nasdaq public historical endpoint
with an SEC-reported share count. The
latest share evidence is dated
2026-04-27
(10-Q,
tag dei:EntityCommonStockSharesOutstanding,
accession 0000875045-26-000045).
Open SEC XBRL evidence.
Open Nasdaq price evidence.
When 36 completed months are available, these observations support
a provisional independent S&P-style leverage calculation.
This reconstruction is not official S&P index data, does not prove
index membership, and does not complete the separate activity-income
screen. DJIM remains unavailable.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About BIOGEN INC. (BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is BIOGEN INC. (BIIB) halal to invest in?
The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is BIOGEN INC.'s debt ratio?
BIOGEN INC.'s debt ratio is 22.3% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are BIOGEN INC.'s key financial metrics?
BIOGEN INC. has a market capitalization of USD 32030M in its listing currency, trailing P/E ratio of 38.4, and revenue of $9.9B. The company maintains a gross margin of 78.3% and a net margin of 8.3%. Return on equity stands at 4.6%.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.